What is the official website of Sandoz Hrvatska ?

The official website of Sandoz Hrvatska is https://www.sandoz.hr/.

What is Sandoz Hrvatska's cybersecurity risk score?

Sandoz Hrvatska has an AI-generated cybersecurity risk score of 751 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Sandoz Hrvatska experienced?

According to Rankiteo, Sandoz Hrvatska currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Sandoz Hrvatska been affected by any supply chain cyber incidents ?

According to Rankiteo, Sandoz Hrvatska has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Sandoz Hrvatska have SOC 2 Type 1 certification ?

According to Rankiteo, Sandoz Hrvatska is not certified under SOC 2 Type 1.

Does Sandoz Hrvatska have SOC 2 Type 2 certification ?

According to Rankiteo, Sandoz Hrvatska does not hold a SOC 2 Type 2 certification.

Does Sandoz Hrvatska comply with GDPR ?

According to Rankiteo, Sandoz Hrvatska is not listed as GDPR compliant.

Does Sandoz Hrvatska have PCI DSS certification ?

According to Rankiteo, Sandoz Hrvatska does not currently maintain PCI DSS compliance.

Does Sandoz Hrvatska comply with HIPAA ?

According to Rankiteo, Sandoz Hrvatska is not compliant with HIPAA regulations.

Does Sandoz Hrvatska have ISO 27001 certification ?

According to Rankiteo,Sandoz Hrvatska is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Sandoz Hrvatska operate in ?

Sandoz Hrvatska operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Sandoz Hrvatska have ?

Sandoz Hrvatska employs approximately 30 people worldwide.

Does Sandoz Hrvatska own any subsidiaries ?

Sandoz Hrvatska presently has no subsidiaries across any sectors.

How many LinkedIn followers does Sandoz Hrvatska have ?

Sandoz Hrvatska's official LinkedIn profile has approximately 3,890 followers.

What is the NAICS classification code for Sandoz Hrvatska ?

Sandoz Hrvatska is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Sandoz Hrvatska have a Crunchbase profile ?

No, Sandoz Hrvatska does not have a profile on Crunchbase.

Does Sandoz Hrvatska have a LinkedIn profile ?

Yes, Sandoz Hrvatska maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/sandoz-hrvatska.

How many cybersecurity incidents has Sandoz Hrvatska experienced ?

As of June 8, 2026, Rankiteo reports that Sandoz Hrvatska has not experienced any cybersecurity incidents.

How many peer or competitor companies does Sandoz Hrvatska have ?

Sandoz Hrvatska has an estimated 5,674 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Sandoz Hrvatska

Boost Score +25 with badge (5 left)

751

/1000

Fair

776

/1000

Fair

Sandoz Hrvatska Vendor Cyber Rating & Cyber Score

sandoz.hr

Add Your Compliance Badge

Sigurnost naših proizvoda, zdravlje i dobrobit pacijenata naši su glavni prioriteti.

Sandoz Hrvatska A.I CyberSecurity Scoring

Scoring History

Sandoz Hrvatska

Sandoz Hrvatska CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Sandoz Hrvatska Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Sandoz Hrvatska

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Sandoz Hrvatska in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Sandoz Hrvatska in 2026.

Incident Types Sandoz Hrvatska vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Sandoz Hrvatska in 2026.

Incident History - Sandoz Hrvatska (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Sandoz Hrvatska Subsidiaries

Sandoz Hrvatska

Pharmaceutical Manufacturing

Website: https://www.sandoz.hr/

Company Size: 51-200 employees

SandozPharmaceutical Manufacturing

Sandoz ItaliaPharmaceutical Manufacturing

Sandoz do BrasilFabricação de produtos farmoquímicos e farmacêuticos

Lek PharmaceuticalsPharmaceutical Manufacturing

Sandoz India Pvt LtdPharmaceutical Manufacturing

Sandoz BelgiumPharmaceutical Manufacturing

Sandoz EgyptPharmaceutical Manufacturing

Sandoz PolskaPharmaceutical Manufacturing

Sandoz Czech RepublicPharmaceutical Manufacturing

Sandoz in DeutschlandPharmaceutical Manufacturing

Sandoz ÖsterreichPharmaceutical Manufacturing

Sandoz Australia & New ZealandPharmaceutical Manufacturing

Sandoz CanadaPharmaceutical Manufacturing

Sandoz UK & IrelandPharmaceutical Manufacturing

Sandoz RomaniaPharmaceutical Manufacturing

Sandoz IberiaPharmaceutical Manufacturing

Sandoz SrbijaPharmaceutical Manufacturing

Sandoz FrancePharmaceutical Manufacturing

Sandoz HungáriaPharmaceutical Manufacturing

Sandoz MéxicoPharmaceutical Manufacturing

Sandoz SverigePharmaceutical Manufacturing

Life at SandozArzneimittelherstellung

Sandoz NederlandPharmaceutical Manufacturing

Sandoz DanmarkPharmaceutical Manufacturing

Loading…

Sandoz Hrvatska Similar Companies

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Loading…

NEWS

Sandoz Hrvatska CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-11466

SUMMARY

A weakness has been identified in zilliztech deep-searcher up to 0.0.2. This affects the function CollectionRouter.invoke of the file deepsearcher/agent/collection_router.py. This manipulation of the argument kwargs causes improper access controls. Remote exploitation of the attack is possible. The exploit has been made available to the public and could be used for attacks. The pull request to fix this issue awaits acceptance.

Published

Date2026-06-07

Updated

Date2026-06-07

RISK INFORMATION (Score: 5.4)

cvss2

Base Score: 5.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:N/A:P

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:N/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.5

Exploitability

2.8

REFERENCES

CVE-2026-11465

SUMMARY

A security flaw has been discovered in songquanpeng one-api up to 0.6.11-preview.7. Affected by this issue is the function Redeem of the file model/redemption.go of the component Redemption Code Top-Up Endpoint. The manipulation results in business logic errors. The attack may be launched remotely. The attack requires a high level of complexity. The exploitation is known to be difficult. The exploit has been released to the public and may be used for attacks. The pull request to fix this issue awaits acceptance.

Published

Date2026-06-07

Updated

Date2026-06-07

RISK INFORMATION (Score: 3.1)

cvss2

Base Score: 2.1

Complexity: HIGH

AV:N/AC:H/Au:S/C:N/I:P/A:N

cvss3

Base Score: 3.1

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:N/I:L/A:N

cvss4

Base Score: 1.3

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:L/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

1.6

REFERENCES

CVE-2026-11464

SUMMARY

A vulnerability was identified in JeecgBoot up to 3.9.2. Affected by this vulnerability is the function queryPageList of the file src\main\java\org\jeecg\modules\system\controller\SysUserController.java of the component User List Endpoint. The manipulation of the argument salt leads to information disclosure. The attack may be initiated remotely. The attack is considered to have high complexity. The exploitation appears to be difficult. The exploit is publicly available and might be used. A fix is planned for the upcoming release.

Published

Date2026-06-07

Updated

Date2026-06-07

RISK INFORMATION (Score: 3.1)

cvss2

Base Score: 2.1

Complexity: HIGH

AV:N/AC:H/Au:S/C:P/I:N/A:N

cvss3

Base Score: 3.1

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:L/I:N/A:N

cvss4

Base Score: 1.3

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

1.6

REFERENCES

CVE-2026-11463

SUMMARY

A vulnerability was determined in USCiLab Cereal up to 1.3.2. Affected is an unknown function of the component Shared Pointer Handler. Executing a manipulation can lead to type confusion. The attack can be launched remotely. The exploit has been publicly disclosed and may be utilized. The vendor was contacted early about this disclosure.

Published

Date2026-06-07

Updated

Date2026-06-07

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

CVE-2026-11462

SUMMARY

A vulnerability was found in Chengdu Everbrite Network Technology BeikeShop up to 1.6.0.22. This impacts the function callback of the file plugins/Stripe/Controllers/StripeController.php of the component Stripe Plugin. Performing a manipulation of the argument Request results in improper authorization. The attack can be initiated remotely. The exploit has been made public and could be used. The patch is named 6719e0fc690ea0a998452092862e0f0a17c65968. It is suggested to install a patch to address this issue.

Published

Date2026-06-07

Updated

Date2026-06-07

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…